At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
Navarixin 10 mg +1 moredrug
Likely dose
Navarixin 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Assess the Clinical Effects of SCH 527123 in Psoriasis
In Brief
A Phase 2 clinical trial evaluating Navarixin 10 mg and Placebo for Psoriasis. Completed, enrolled 31 participants.
Detailed Summary
This study was conducted: 1) to assess the clinical effect of Navarixin on the Psoriasis Activity and Severity Index (PASI), 2) to determine the effects of Navarixin on the Physician's Global Assessment (PGA), 3) to evaluate the safety and tolerability of Navarixin, and 4) to determine the multiple-dose pharmacokinetics of Navarixin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2007
Primary CompletionOct 2007
First PostedMay 2008
TodayJul 2026
First PostedMay 26, 2008
Enrollment StartJun 1, 2007
Primary CompletionOct 1, 2007
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 18.1 years ago
Interventions
Navarixin 10 mgdrug
Navarixin capsules orally, once daily for 28 days.
Placeboother
Matching placebo capsules to Navarixin orally, once daily for 28 days.